John Schindler

5.5k total citations · 2 hit papers
56 papers, 4.3k citations indexed

About

John Schindler is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, John Schindler has authored 56 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Immunology, 13 papers in Radiology, Nuclear Medicine and Imaging and 12 papers in Oncology. Recurrent topics in John Schindler's work include Toxin Mechanisms and Immunotoxins (18 papers), Immune Cell Function and Interaction (14 papers) and Monoclonal and Polyclonal Antibodies Research (13 papers). John Schindler is often cited by papers focused on Toxin Mechanisms and Immunotoxins (18 papers), Immune Cell Function and Interaction (14 papers) and Monoclonal and Polyclonal Antibodies Research (13 papers). John Schindler collaborates with scholars based in United States, Germany and France. John Schindler's co-authors include Robert L. Hirsch, Hillel Panitch, Kenneth P. Johnson, Ellen S. Vitetta, Victor Gheţie, Malcolm K. Brenner, Antonio Di Stasi, Siok‐Keen Tey, Yuriko Fujita and Alana A. Kennedy‐Nasser and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

John Schindler

55 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

2011 1.2k citations Antonio Di Stasi, Siok‐Keen Tey et al. New England Journal of Medicine profile →
Treatment of multiple sclerosis with gamma interferon

1987 609 citations John Schindler et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Schindler United States	32	2.3k	1.7k	1.0k	732	545	56	4.3k
C. Garrison Fathman United States	45	5.3k 2.3×	1.1k 0.7×	1.6k 1.6×	1.1k 1.5×	342 0.6×	112	7.4k
Ada M. Kruisbeek Netherlands	49	5.4k 2.3×	1.8k 1.1×	2.0k 2.0×	684 0.9×	181 0.3×	122	7.3k
Yasuharu Nishimura Japan	44	3.0k 1.3×	1.8k 1.1×	2.6k 2.6×	436 0.6×	259 0.5×	171	6.0k
B. J. Fowlkes United States	45	5.7k 2.4×	1.3k 0.8×	1.8k 1.7×	474 0.6×	139 0.3×	77	7.5k
Dale Ando United States	30	2.3k 1.0×	1.3k 0.8×	2.3k 2.3×	1.5k 2.0×	321 0.6×	55	5.4k
Ronald Palacios Sweden	40	3.2k 1.4×	923 0.5×	1.5k 1.5×	391 0.5×	187 0.3×	100	5.1k
Robert S. Mittler United States	50	6.4k 2.8×	2.6k 1.5×	1.5k 1.5×	515 0.7×	183 0.3×	105	8.2k
Richard J. Bram United States	35	3.2k 1.4×	899 0.5×	2.7k 2.7×	775 1.1×	300 0.6×	76	6.2k
Roland Scollay Australia	51	6.6k 2.8×	1.5k 0.9×	2.1k 2.1×	894 1.2×	152 0.3×	132	9.1k
Matteo Bellone Italy	36	2.6k 1.1×	1.6k 1.0×	1.8k 1.8×	291 0.4×	108 0.2×	110	4.6k

Countries citing papers authored by John Schindler

Since Specialization

Citations

This map shows the geographic impact of John Schindler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Schindler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Schindler more than expected).

Fields of papers citing papers by John Schindler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Schindler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Schindler. The network helps show where John Schindler may publish in the future.

Co-authorship network of co-authors of John Schindler

This figure shows the co-authorship network connecting the top 25 collaborators of John Schindler. A scholar is included among the top collaborators of John Schindler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Schindler. John Schindler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Xiaoyun, Laurentiu M. Pop, John Schindler, & Ellen S. Vitetta. (2012). Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity. mAbs. 4(1). 57–68. 22 indexed citations

Vitetta, Ellen S., Joan E. Smallshaw, & John Schindler. (2012). Pilot Phase IB Clinical Trial of an Alhydrogel-Adsorbed Recombinant Ricin Vaccine. Clinical and Vaccine Immunology. 19(10). 1697–1699. 43 indexed citations

Barta, Stefan K., Yiyu Zou, John Schindler, et al.. (2012). Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia. Leukemia & lymphoma. 53(10). 1999–2003. 23 indexed citations

Schindler, John, Farhad Ravandi, Yu‐Min Shen, et al.. (2011). A phase I study of a combination of anti‐CD19 and anti‐CD22 immunotoxins (Combotox) in adult patients with refractory B‐lineage acute lymphoblastic leukaemia. British Journal of Haematology. 154(4). 471–476. 69 indexed citations

Stasi, Antonio Di, Siok‐Keen Tey, Gianpietro Dotti, et al.. (2011). Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy. New England Journal of Medicine. 365(18). 1673–1683. 1159 indexed citations breakdown →

Herrera, Larry, Bruce Bostrom, Eric Sandler, et al.. (2009). A Phase 1 Study of Combotox in Pediatric Patients With Refractory B-lineage Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology. 31(12). 936–941. 73 indexed citations

Powell, Daniel J., Peter Attia, Victor Gheţie, et al.. (2008). Partial Reduction of Human FOXP3+ CD4 T Cells In Vivo After CD25-directed Recombinant Immunotoxin Administration. Journal of Immunotherapy. 31(2). 189–198. 51 indexed citations

Schindler, John, et al.. (2007). Identification and quantification of high fluorescence‐stained lymphocytes as antibody synthesizing/secreting cells using the automated routine hematology analyzer XE‐2100. Cytometry Part B Clinical Cytometry. 72B(3). 157–166. 36 indexed citations

Martin, Paul J., Ji Pei, Ted Gooley, et al.. (2004). Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biology of Blood and Marrow Transplantation. 10(8). 552–560. 47 indexed citations

10.

Solomon, Scott R., Charles S. Carter, John Schindler, et al.. (2002). Optimized clinical-scale culture conditions for ex vivoselective depletion of host-reactive donor lymphocytes: astrategy for GVHD prophylaxis in allogeneic peripheral bloodstem cell transplantation. Cytotherapy. 4(5). 1 indexed citations

11.

André‐Schmutz, Isabelle, Françoise Le Deist, Salima Hacein‐Bey‐Abina, et al.. (2002). Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. The Lancet. 360(9327). 130–137. 168 indexed citations

12.

Solomon, Scott R., Thuong Hien Tran, Sheila Donnelly, et al.. (2002). Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy. 4(5). 395–406. 51 indexed citations

13.

André‐Schmutz, Isabelle, Françoise Le Deist, Salima Hacein‐Bey, et al.. (2002). Donor T lymphocyte infusion following ex vivo depletion of donor anti-host reactivity by a specific anti–interleukin-2 receptor P55 chain immunotoxin. Transplantation Proceedings. 34(7). 2927–2928. 12 indexed citations

14.

Schindler, John, E. A. Sausville, Richard A. Messmann, J W Uhr, & E S Vitetta. (2001). The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials.. PubMed. 7(2). 255–8. 39 indexed citations

15.

Schnell, R., E S Vitetta, John Schindler, et al.. (2000). Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia. 14(1). 129–135. 56 indexed citations

16.

Schnell, R., E S Vitetta, John Schindler, et al.. (1998). Clinical Trials with an Anti-CD25 Ricin A-Chain Experimental and Immunotoxin (RFT5-SMPT-dgA) in Hodgkin's Lymphoma. Leukemia & lymphoma. 30(5-6). 525–538. 47 indexed citations

17.

Schnell, R., Gisela Schön, Heribert Bohlen, et al.. (1995). 930 A clinical phase I study of an anti-CD25-deglycosylated ricin A-chain immunotoxin (RFT5-SMPT-DGA) in patients with refractory Hodgkin's disease. European Journal of Cancer. 31. S193–S193. 2 indexed citations

18.

Schwander, Stephan, et al.. (1994). Phase I/II vaccination study of recombinant peptide F46 corresponding to the HIV-1 transmembrane protein coupled with 2.4 dinitrophenyl (DNP) Ficoll. Infection. 22(2). 86–91. 8 indexed citations

19.

Gambacorti‐Passerini, Carlo, Marina Radrizzani, Raffaele Marolda, et al.. (1988). In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2. International Journal of Cancer. 41(5). 700–706. 26 indexed citations

20.

Köller, Ursula, et al.. (1987). Incidence of Anti HIV Antibodies and Viral Antigen in Standard and Control sera. Clinical Chemistry and Laboratory Medicine (CCLM). 25(10). 705–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact